Variables | # of Studies | Point Estimate | 95Â % CI | |
---|---|---|---|---|
Start year of study | Â | Â | Â | Â |
12 | 0.64 | 0.54 | 0.74 | |
4 | 0.60 | 0.44 | 0.77 | |
Quality of study | Â | Â | Â | Â |
11 | 0.65 | 0.54 | 0.75 | |
5 | 0.59 | 0.44 | 0.74 | |
Adverse Events | Â | Â | Â | Â |
3 | 0.76 | 0.70 | 0.82 | |
8 | 0.63 | 0.52 | 0.73 | |
Type of treated patients | Â | Â | Â | Â |
 New cases and previously treated [6, 30–32, 34–37, 39, 41, 42] | 11 | 0.61 | 0.52 | 0.71 |
4 | 0.66 | 0.53 | 0.78 | |
HIV co-infected patientsa | Â | Â | Â | Â |
10 | 0.57 | 0.49 | 0.64 | |
6 | 0.72 | 0.65 | 0.79 | |
Patient type | Â | Â | Â | Â |
12 | 0.67 | 0.56 | 0.78 | |
3 | 0.51 | 0.48 | 0.55 | |
 XDR [38] | 1 | 0.48 | 0.30 | 0.66 |
DOTS-plus Provider | Â | Â | Â | Â |
8 | 0.59 | 0.48 | 0.69 | |
2 | 0.78 | 0.60 | 0.95 | |
 Home care support teams [14] | 1 | 0.71 | 0.62 | 0.80 |
2 | 0.72 | 0.61 | 0.83 | |
 Family [34] | 1 | 0.79 | 0.72 | 0.86 |
Drug Regimen Model | Â | Â | Â | Â |
9 | 0.66 | 0.53 | 0.79 | |
6 | 0.57 | 0.51 | 0.62 | |
DOTS-plus Location | Â | Â | Â | Â |
4 | 0.70 | 0.56 | 0.84 | |
 Patient home [6] | 1 | 0.84 | 0.76 | 0.92 |
4 | 0.61 | 0.53 | 0.68 | |
7 | 0.57 | 0.44 | 0.69 | |
Duration of DOTS-plusa | Â | Â | Â | Â |
9 | 0.72 | 0.65 | 0.79 | |
5 | 0.50 | 0.43 | 0.57 | |
Length of treatment (months)a | Â | Â | Â | Â |
2 | 0.48 | 0.42 | 0.55 | |
12 | 0.65 | 0.56 | 0.74 | |
Drugs in regimena | Â | Â | Â | Â |
11 | 0.57 | 0.49 | 0.64 | |
2 | 0.82 | 0.76 | 0.89 |